Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
ICD Ablation plus VT-ablation
Rhythm Pharmaceuticals Netherlands B.V.
Tachycardia, Ventricular
1 trial -
ICS/LABA
The First People's Hospital of Lianyungang
Asthma
1 trial -
INDOCYANINE GREEN
The George Institute
Patients with liver tumors that will undergo minimally invasive liver surgery
1 trial -
INFLUENZA, INACTIVATED, SPLIT VIRUS OR SURFACE ANTIGEN
The George Institute
Influenza, Immunity against influenza
1 trial -
IVC
The First People's Hospital of Lianyungang
Proliferative Diabetic Retinopathy
1 trial -
Ibrutinib
AbbVie Deutschland GmbH & Co. KG
1. Follicular Lymphoma 2. Chronic Lymphocytic Leukemia 3. Waldenstrom macroglobulinemia 4. Multiple Myeloma 5. Marginal Zone Lymphoma 6. Diffuse Large B-Cell Lymphoma 7. Urothelial Carcinoma 8. Breast Cancer 9. Acute Myeloid Leukemia 10. Graft vs Host Disease 11. Mantle Cell Lymphoma
1 trial -
Icodextrin Peritoneal Dialysis Solution
The First People's Hospital of Lianyungang
Peritoneal Dialysis
1 trial -
Iloperidone
Vanda Pharmaceuticals Netherlands B.V.
Schizophrenia
5 trials -
Imiquimod
United Therapeutics Europe Ltd
Lentigo Maligna
1 trial -
Implantable Cardiac Defibrillator
Rhythm Pharmaceuticals Netherlands B.V.
Tachycardia, Ventricular
2 trials -
Implantable Cardiac Monitor
Rhythm Pharmaceuticals Netherlands B.V.
Chagas Disease
1 trial -
Implantable Defibrillator
Rhythm Pharmaceuticals Netherlands B.V.
Heart Disease
1 trial -
Implantable cardioverter defibrillator
Rhythm Pharmaceuticals Netherlands B.V.
Acute Myocardial Infarction
1 trial -
Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 2
Sinovac Research and Development Co.,
COVID-19
1 trial -
Individual ATG
The First People's Hospital of Lianyungang
Hematopoietic Stem Cell Transplantation
1 trial -
Infliximab
The First People's Hospital of Lianyungang
Crohn's Diseases
1 trial -
Initiating daily oral PrEP during pregnancy
United Therapeutics Europe Ltd
Pre-exposure Prophylaxis
1 trial -
Insulin
The First People's Hospital of Lianyungang
Brain Injuries
1 trial -
Insulin
The First People's Hospital of Lianyungang
Acute Pancreatitis
1 trial -
Intranasal dexmedetomidine-esketamine
The First People's Hospital of Lianyungang
Adenotonsillectomy
1 trial -
Intrathecal (injected into the spinal fluid) DepoCyt
Pacira Ireland Limited
Meningeal Neoplasms
1 trial -
Intrathecal morphine injection
Pacira Ireland Limited
Pain
1 trial -
Intravenous Immunoglobulins, Human
The First People's Hospital of Lianyungang
Guillain-Barre Syndrome
1 trial -
Intravenous Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy in Adult Patients with Atrial Fibrillation
Rhythm Pharmaceuticals Netherlands B.V.
Arrhythmias, Cardiac
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources